Tech was leading the way lower for stocks Wednesday. BTIG Chief Market Technician Jonathan Krinsky noted that while tech ...
BTIG raised the firm’s price target on Upwork (UPWK) to $18 from $16 and keeps a Buy rating on the shares as part of a broader research note ...
Fintel reports that on December 2, 2024, BTIG initiated coverage of BrightView Holdings (NYSE:BV) with a Buy recommendation.
Fintel reports that on December 2, 2024, BTIG downgraded their outlook for AnaptysBio (NasdaqGS:ANAB) from Buy to Neutral.
Investing.com -- According to a note from BTIG on Monday, the tech sector's ongoing weakness is raising concerns as markets ...
BTIG downgraded AnaptysBio (ANAB) to Neutral from Buy without a price target The company’s topline data from the Phase 2b trial of ANB032 in ...
As of the latest trading close, AKBA, a Healthcare sector stock, is trading -14.11% below its 52-week high but remains 166.25% above its 52-week low. The Average True Range (ATR) (14 days) of 0.1 ...
Outlook Therapeutics (NASDAQ:OTLK – Free Report) had its target price reduced by BTIG Research from $50.00 to $9.00 in a ...
Embecta (EMBC) stock gains as BTIG upgrades the stock citing an end to its patch pump program announced with its Q4 FY24 ...
Organogenesis Holdings Inc (ORGO) stock saw a decline, ending the day at $3.86 which represents a decrease of $-0.01 or -0.26% from the prior close of $3.87. The stock opened at $3.93 and touched a ...
BTIG lowered the firm’s price target on Outlook Therapeutics (OTLK) to $9 from $50 and keeps a Buy rating on the shares. The ...
HealthEquity (NASDAQ:HQY – Free Report) had its price target boosted by Barrington Research from $105.00 to $120.00 in a ...